Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Beta Bionics, Inc. and Tandem Diabetes Care, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Beta Bionics, Inc. (BBNX $20.01) and Tandem Diabetes Care, Inc. (TNDM $23.46), medical technology companies that develop, manufacture, and market automated insulin delivery systems for the management of diabetes.

    Read more

  • Rideshare Growth Incrementally Driven by Power Users

    With new rider growth slowing, rideshare platforms are betting on power users to drive the next phase of expansion.

    Read more

  • Surrozen, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Surrozen, Inc. (SRZN $24.00), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures